title: Testosterone and metabolic syndrome: a meta-analysis study.
abstract: BACKGROUND
  Metabolic syndrome (MetS) is often associated with male hypogonadism. Despite the well-known link, the role of testosterone replacement therapy (TRT) in MetS has not been completely clarified.
  
  
  OBJECTIVE
  To systematically analyse the relationship between androgen levels and MetS we performed a review and meta-analyses of available prospective and cross-sectional studies. In addition, a specific meta-analysis on the metabolic effects of TRT in available randomized clinical trials (RCTs) was also performed.
  
  
  METHODS
  An extensive Medline search was performed including the following words "testosterone,""metabolic syndrome," and "males".
  
  
  METHODS
  Out of 323 retrieved articles, 302 articles were excluded for different reasons. Among the 20 published studies included, 13, 3, and 4 were cross-sectional, longitudinal, and RCTs, respectively. Another unpublished RCT was retrieved on http://www.clinicaltrials.gov.
  
  
  RESULTS
  MetS patients showed significantly lower T plasma levels, as compared with healthy individuals. Similar results were obtained when MetS subjects with and without erectile dysfunction were analyzed separately or when NCEP-ATPIII MetS criteria were compared with other definitions. Meta-regression analysis demonstrated that type 2 diabetes (T2DM) increased the MetS-associated T fall. In a multiple regression model, after adjusting for age and BMI, both T2DM and MetS independently predicted low testosterone (adj. r = -0.752; P < 0.001 and -0.271; P < 0.05, respectively). Analysis of longitudinal studies demonstrated that baseline testosterone was significantly lower among patients with incident MetS in comparison with controls (2.17 [-2.41;-1.94] nmol/L; P < 0.0001). Combining the results of RCTs, TRT was associated with a significant reduction of fasting plasma glucose, homeostatic model assessment index, triglycerides, and waist circumference. In addition, an increase of high-density lipoprotein cholesterol was also observed.
  
  
  CONCLUSIONS
  The meta-analysis of the available cross-sectional data suggests that MetS can be considered an independent association of male hypogonadism. Although only few RCTs have been reported, TRT seems to improve metabolic control, as well as central obesity.
authors.affiliation: Andrology and Sexual Medicine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Corona
authors.forename: Matteo
authors.initials: M
authors.lastname: Monami
authors.forename: Giulia
authors.initials: G
authors.lastname: Rastrelli
authors.forename: Antonio
authors.initials: A
authors.lastname: Aversa
authors.forename: Yuliya
authors.initials: Y
authors.lastname: Tishova
authors.forename: Farid
authors.initials: F
authors.lastname: Saad
authors.forename: Andrea
authors.initials: A
authors.lastname: Lenzi
authors.forename: Gianni
authors.initials: G
authors.lastname: Forti
authors.forename: Edoardo
authors.initials: E
authors.lastname: Mannucci
authors.forename: Mario
authors.initials: M
authors.lastname: Maggi
mesh_terms: D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology / Q000517:prevention & control*; D015999:Multivariate Analysis; D012044:Regression Analysis; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D013739:Testosterone